Corgenix gets grant to develop Ebola and Marburg virus tests
This article was originally published in Clinica
The US National Institutes of Health has awarded IVD firm Corgenix Medical a $600,000 grant to help develop tests for two tropical viruses: Ebola and Marburg. The grant will support a two-year study, which Corgenix expects to aid the development of “specific, cost-effective and easy-to-use tests” for both viruses. These could eventually lead to vaccines and treatments, the Denver, Colorado company hopes. Several other institutions are collaborating on the project, including Tulane University in New Orleans, Louisiana, and The Scripps Research Institute in La Jolla, California. Both the Ebola and Marburg viruses are found in Africa and cause haemorrhagic fevers, characterised by bleeding and coagulation abnormalities. Ebola is fatal in up to 90% of cases.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.